Graft-versus-Leukemia Effect Following Hematopoietic Stem Cell Transplantation for Leukemia

The success of hematopoietic stem cell transplantation (HSCT) lies with the ability of the engrafting immune system to remove residual leukemia cells via a graft-versus-leukemia effect (GvL), caused either spontaneously post-HSCT or via donor lymphocyte infusion. GvL effects can also be initiated by allogenic mismatched natural killer cells, antigen-specific T cells, and activated dendritic cells of leukemic origin. The history and further application of this GvL effect and the main mechanisms will be discussed and reviewed in this chapter.

[1]  Giovanna Lombardi,et al.  Treg therapy in transplantation: a general overview , 2017, Transplant international : official journal of the European Society for Organ Transplantation.

[2]  Ya-Zhen Qin,et al.  The dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell transplantation predict relapse in patients with t(8;21) acute myeloid leukemia , 2017, Journal of Hematology & Oncology.

[3]  H. Kolb,et al.  Long-term results of adjuvant donor lymphocyte transfusion in AML after allogeneic stem cell transplantation , 2016, Bone Marrow Transplantation.

[4]  J. Falkenburg,et al.  Autosomal Minor Histocompatibility Antigens: How Genetic Variants Create Diversity in Immune Targets , 2016, Front. Immunol..

[5]  A. Gennery,et al.  Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually , 2016, Bone Marrow Transplantation.

[6]  N. Kröger,et al.  Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease? , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[7]  S. Rutella,et al.  Revving up Natural Killer Cells and Cytokine-Induced Killer Cells Against Hematological Malignancies , 2015, Front. Immunol..

[8]  E. Bonifacio,et al.  Adoptive transfer of allogeneic regulatory T cells into patients with chronic graft-versus-host disease. , 2015, Cytotherapy.

[9]  B. Falini,et al.  HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse. , 2014, Blood.

[10]  Weiqun Yan,et al.  Expansion of NK cells by engineered K562 cells co-expressing 4-1BBL and mMICA, combined with soluble IL-21. , 2014, Cellular immunology.

[11]  L. Weiner,et al.  CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets. , 2014, Blood.

[12]  A. Ohta,et al.  Extracellular Adenosine-Mediated Modulation of Regulatory T Cells , 2014, Front. Immunol..

[13]  D. Busch,et al.  CD4(+)and CD8(+)T-cell reactions against leukemia-associated- or minor-histocompatibility-antigens in AML-patients after allogeneic SCT. , 2014, Immunobiology.

[14]  R. Buhmann,et al.  P65. Minor-histocompatibility-antigen UTY as target for graft-versus-leukaemia and graft-versus-haematopoiesis in the canine-model , 2014, Journal of Immunotherapy for Cancer.

[15]  L. Giordano,et al.  Unmanipulated haploidentical BMT following non-myeloablative conditioning and post-transplantation CY for advanced Hodgkin’s lymphoma , 2014, Bone Marrow Transplantation.

[16]  R. Willemze,et al.  Myeloablative T cell-depleted alloSCT with early sequential prophylactic donor lymphocyte infusion is an efficient and safe post-remission treatment for adult ALL , 2014, Bone Marrow Transplantation.

[17]  Lanping Xu,et al.  Chemotherapy followed by modified donor lymphocyte infusion as a treatment for relapsed acute leukemia after haploidentical hematopoietic stem cell transplantation without in vitro T‐cell depletion: superior outcomes compared with chemotherapy alone and an analysis of prognostic factors , 2013, European journal of haematology.

[18]  M. Caligiuri,et al.  CS1-Specific Chimeric Antigen Receptor (CAR)-Engineered Natural Killer Cells Enhance In Vitro and In Vivo Anti-tumor Activity Against Human Multiple Myeloma , 2013, Leukemia.

[19]  M. Griffioen,et al.  HLA class II upregulation during viral infection leads to HLA-DP-directed graft-versus-host disease after CD4+ donor lymphocyte infusion. , 2013, Blood.

[20]  K. Peggs.  Attack of the T-cell clones. , 2013, Blood.

[21]  Bin Zhang,et al.  Targeting Natural Killer Cells to Acute Myeloid Leukemia In Vitro with a CD16 × 33 Bispecific Killer Cell Engager and ADAM17 Inhibition , 2013, Clinical Cancer Research.

[22]  M. Smyth,et al.  Molecular mechanisms of natural killer cell activation in response to cellular stress , 2013, Cell Death and Differentiation.

[23]  G. Mufti,et al.  Outcome of donor lymphocyte infusion after T cell-depleted allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromes. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[24]  T. D. de Gruijl,et al.  Priming of PRAME- and WT1-specific CD8+ T cells in healthy donors but not in AML patients in complete remission , 2013, Oncoimmunology.

[25]  D. Kaufman,et al.  Clinical‐Scale Derivation of Natural Killer Cells From Human Pluripotent Stem Cells for Cancer Therapy , 2013, Stem cells translational medicine.

[26]  R. Sposto,et al.  Growth and Activation of Natural Killer Cells Ex Vivo from Children with Neuroblastoma for Adoptive Cell Therapy , 2013, Clinical Cancer Research.

[27]  Arndt Borkhardt,et al.  In vitro-induced response patterns of antileukemic T cells: characterization by spectratyping and immunophenotyping , 2013, Clinical and Experimental Medicine.

[28]  N. Kröger,et al.  Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation , 2013, Leukemia.

[29]  M. Kneba,et al.  Has MRD monitoring superseded other prognostic factors in adult ALL? , 2012, Blood.

[30]  M. Caligiuri,et al.  A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. , 2012, Blood.

[31]  K. Götze,et al.  High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses , 2012, Leukemia.

[32]  V. Morris.  NK Cell Activation through KIR-HLA Interactions Decreases Leukemia Relapse after Transplant , 2012 .

[33]  L. Weiner,et al.  Bispecific and Trispecific Killer Cell Engagers Directly Activate Human NK Cells through CD16 Signaling and Induce Cytotoxicity and Cytokine Production , 2012, Molecular Cancer Therapeutics.

[34]  K. Döhner,et al.  Mutated regions of nucleophosmin 1 elicit both CD4(+) and CD8(+) T-cell responses in patients with acute myeloid leukemia. , 2012, Blood.

[35]  Dean Anthony Lee,et al.  Engineering lymph node homing of ex vivo-expanded human natural killer cells via trogocytosis of the chemokine receptor CCR7. , 2012, Blood.

[36]  T. Kondo,et al.  Expansion of NK cells from cord blood with antileukemic activity using GMP-compliant substances without feeder cells , 2012, Leukemia.

[37]  S. Lonial,et al.  Panobinostat for the treatment of multiple myeloma , 2012, Expert opinion on investigational drugs.

[38]  Lei Zhang,et al.  Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer , 2012, Nature Medicine.

[39]  Wen Jiang,et al.  Natural killer cell lines in tumor immunotherapy , 2012, Frontiers of Medicine.

[40]  C. Schmid,et al.  The T-Cells’ Role in Antileukemic Reactions - Perspectives for Future Therapies’ , 2012 .

[41]  N. Kröger,et al.  Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. , 2012, Blood.

[42]  R. Wäsch,et al.  Induction of graft versus malignancy effect after unrelated allogeneic PBSCT using donor lymphocyte infusions derived from frozen aliquots of the original graft , 2012, Bone Marrow Transplantation.

[43]  L. Hurton,et al.  Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells , 2012, PloS one.

[44]  Xiao-jun Huang,et al.  Conflicting impact of alloreactive NK cells on transplantation outcomes after haploidentical transplantation: do the reconstitution kinetics of natural killer cells create these differences? , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[45]  M. Edinger,et al.  Regulatory T cells in stem cell transplantation: strategies and first clinical experiences. , 2011, Current opinion in immunology.

[46]  S. Riddell,et al.  Exploiting T cells specific for human minor histocompatibility antigens for therapy of leukemia , 2011, Immunology and cell biology.

[47]  Dean Anthony Lee,et al.  Expansion, purification, and functional assessment of human peripheral blood NK cells. , 2011, Journal of visualized experiments : JoVE.

[48]  J. Wagner,et al.  Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. , 2011, Blood.

[49]  F. Locatelli,et al.  Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation. , 2011, Blood.

[50]  M. Rondoni,et al.  Complete molecular response in CML after p210 BCR–ABL1-derived peptide vaccination , 2010, Nature Reviews Clinical Oncology.

[51]  Marcela R. Uribe,et al.  Donor KIR Genes 2DL5A, 2DS1 and 3DS1 are associated with a reduced rate of leukemia relapse after HLA-identical sibling stem cell transplantation for acute myeloid leukemia but not other hematologic malignancies. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[52]  S. Mackinnon,et al.  T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  J. Klein,et al.  Decreased infections in recipients of unrelated donor hematopoietic cell transplantation from donors with an activating KIR genotype. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[54]  Ş. Akı,et al.  Donor lymphocyte infusion for leukemia relapse after hematopoietic stem cell transplantation. , 2010, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[55]  K. Hsu,et al.  Donor activating KIR3DS1 is associated with decreased acute GVHD in unrelated allogeneic hematopoietic stem cell transplantation. , 2010, Blood.

[56]  G. Ledderose,et al.  Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells. , 2010, Blood.

[57]  R. Negrin,et al.  Biology and clinical effects of natural killer cells in allogeneic transplantation , 2010, Current opinion in oncology.

[58]  S. Iacobelli,et al.  Outcome of patients developing GVHD after DLI given to treat CML relapse: a study by the chronic leukemia working party of the EBMT , 2010, Bone Marrow Transplantation.

[59]  R. Childs,et al.  Cutting Edge: Bortezomib-Treated Tumors Sensitized to NK Cell Apoptosis Paradoxically Acquire Resistance to Antigen-Specific T Cells , 2009, The Journal of Immunology.

[60]  S. Mielke,et al.  Management of relapse after allo-SCT for AML and the role of second transplantation , 2009, Bone Marrow Transplantation.

[61]  J. Falkenburg,et al.  Identification of 4 new HLA-DR-restricted minor histocompatibility antigens as hematopoietic targets in antitumor immunity. , 2009, Blood.

[62]  J. Myśliwska,et al.  First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells. , 2009, Clinical immunology.

[63]  R. Storb,et al.  What is the role for donor natural killer cells after nonmyeloablative conditioning? , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[64]  K. Rezvani,et al.  Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia. , 2009, Blood.

[65]  I. Lowy,et al.  CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. , 2009, Blood.

[66]  M. Labopin,et al.  KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia , 2009, Leukemia.

[67]  R. Fanin,et al.  Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia , 2009, European journal of haematology.

[68]  H. Kolb.  Graft-versus-leukemia effects of transplantation and donor lymphocytes. , 2008, Blood.

[69]  M. Maris,et al.  Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[70]  A. Velardi.  Role of KIRs and KIR ligands in hematopoietic transplantation. , 2008, Current opinion in immunology.

[71]  A. Barrett.  Understanding and harnessing the graft‐versus‐leukaemia effect , 2008, British journal of haematology.

[72]  H. Dombret,et al.  Acute myeloid leukemia in the elderly. , 2008, Seminars in oncology.

[73]  J. Cornelissen,et al.  Allogeneic stem cell transplantation in acute myeloid leukemia in first or subsequent remission: weighing prognostic markers predicting relapse and risk factors for non-relapse mortality. , 2008, Seminars in oncology.

[74]  C. Craddock.  Full-intensity and reduced-intensity allogeneic stem cell transplantation in AML , 2008, Bone Marrow Transplantation.

[75]  R. Schlenk,et al.  RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses. , 2008, Blood.

[76]  W. Shannon,et al.  45: Development of Antibodies to Self Antigens K-alpha-1 Tubulin and Collagen V in Patients with Chronic Graft Versus Host Disease , 2008 .

[77]  M. Labopin,et al.  Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  P. Marks,et al.  Histone deacetylase inhibitors: molecular mechanisms of action , 2007, Oncogene.

[79]  R. Raymakers,et al.  Multiple myeloma patients receiving pre-emptive donor lymphocyte infusion after partial T-cell-depleted allogeneic stem cell transplantation show a long progression-free survival , 2007, Bone Marrow Transplantation.

[80]  F. Dazzi,et al.  Disease relapse after haematopoietic stem cell transplantation: risk factors and treatment. , 2007, Best practice & research. Clinical haematology.

[81]  P. Parham,et al.  Donor-recipient combinations of group A and B KIR haplotypes and HLA class I ligand affect the outcome of HLA-matched, sibling donor hematopoietic cell transplantation. , 2007, Human immunology.

[82]  A. Kremser,et al.  Quantification of ex vivo generated dendritic cells (DC) and leukemia-derived DC contributes to estimate the quality of DC, to detect optimal DC-generating methods or to optimize DC-mediated T-cell-activation-procedures ex vivo or in vivo , 2007, Leukemia.

[83]  J. Wagner,et al.  Lymphodepletion followed by donor lymphocyte infusion (DLI) causes significantly more acute graft-versus-host disease than DLI alone. , 2006, Blood.

[84]  A. Barrett,et al.  Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents , 2006, Leukemia.

[85]  D. Schrump,et al.  Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity. , 2006, Cancer research.

[86]  W. Siegert,et al.  Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[87]  G. Ledderose,et al.  Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[88]  D. Campana,et al.  Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. , 2005, Blood.

[89]  G. Ledderose,et al.  CD6-depleted mobilized stem cells for modification of HVG and GVH reactions after HLA-haploidentical marrow transplantation , 2005 .

[90]  J. Finke,et al.  Donor lymphocyte infusions for multiple myeloma: clinical results and novel perspectives , 2004, Bone Marrow Transplantation.

[91]  G. Ledderose,et al.  CD6-Depleted Mobilized Stem Cells for Modification of HVG and GVH Reactions after HLA-Haploidentical Marrow Transplantation. , 2004 .

[92]  A. Raptis,et al.  Adoptive immunotherapy with donor lymphocyte infusions and interleukin-2 after high-dose therapy and autologous stem cell rescue for multiple myeloma , 2004, Bone Marrow Transplantation.

[93]  G. Ledderose,et al.  In-vivo generation of leukaemia-derived dendritic cells. , 2004, Best practice & research. Clinical haematology.

[94]  G. Ledderose,et al.  Low-dose ARAC, donor cells, and GM-CSF for treatment of recurrent acute myeloid leukemia after allogeneic stem cell transplantation , 2004, Leukemia.

[95]  M. Voso,et al.  Identification of a Novel Subpopulation of Human Cord Blood CD34−CD133−CD7−CD45+Lineage− Cells Capable of Lymphoid/NK Cell Differentiation After In Vitro Exposure to IL-15 1 , 2003, The Journal of Immunology.

[96]  Santhosh K. P. Kumar,et al.  Lymphocyte recovery after allogeneic bone marrow transplantation predicts risk of relapse in acute lymphoblastic leukemia , 2003, Leukemia.

[97]  J. Falkenburg,et al.  Minor histocompatibility antigens in human stem cell transplantation. , 2003, Experimental hematology.

[98]  Els Goulmy,et al.  Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[99]  B. Horisberger,et al.  Current trends in hematopoietic stem cell transplantation in Europe. , 2002, Blood.

[100]  R. Brand,et al.  Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose. , 2002, Blood.

[101]  Catherine J. Wu,et al.  Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myeloma. , 2002, Blood.

[102]  C. Craddock,et al.  Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation. , 2002, Blood.

[103]  B. Storer,et al.  Factors associated with outcome after unrelated marrow transplantation for treatment of acute lymphoblastic leukemia in children. , 2002, Blood.

[104]  J. Gribben,et al.  T-cell--depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect. , 2001, Blood.

[105]  H. Kolb,et al.  Leukemic dendritic cells generated in the presence of FLT3 ligand have the capacity to stimulate an autologous leukemia-specific cytotoxic T cell response from patients with acute myeloid leukemia , 2001, Leukemia.

[106]  D. Schendel,et al.  Impaired expression of the CD3‐zeta chain in peripheral blood T cells of patients with chronic myeloid leukaemia results in an increased susceptibility to apoptosis , 2000, British journal of haematology.

[107]  H J Kolb,et al.  Interferon alpha in combination with GM‐CSF induces the differentiation of leukaemic antigen‐presenting cells that have the capacity to stimulate a specific anti‐leukaemic cytotoxic T‐cell response from patients with chronic myeloid leukaemia , 2000, British journal of haematology.

[108]  H. Kolb,et al.  Interferon alpha in combination with GM-CSF induces the differentiation of leukaemic antigen-presenting cells that have the capacity to stimulate a specific anti-leukaemic cytotoxic T-cell response from patients with chronic myeloid leukaemia. , 2000 .

[109]  C. Craddock,et al.  Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. , 2000, Blood.

[110]  J. Goldman,et al.  Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. , 2000, Blood.

[111]  J. Goldman,et al.  Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplant: where we now stand. , 1999, Experimental hematology.

[112]  J. Connors,et al.  Long-term follow-up of patients who achieved complete remission after donor leukocyte infusions. , 1999, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[113]  A. Elmaagacli,et al.  Influence of intestinal bacterial decontamination using metronidazole and ciprofloxacin or ciprofloxacin alone on the development of acute graft-versus-host disease after marrow transplantation in patients with hematologic malignancies: final results and long-term follow-up of an open-label prospect , 1999, Blood.

[114]  Polly Matzinger,et al.  A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell , 1998, Nature.

[115]  M. Llano,et al.  HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[116]  J. Coligan,et al.  Recognition of Human Histocompatibility Leukocyte Antigen (HLA)-E Complexed with HLA Class I Signal Sequence–derived Peptides by CD94/NKG2 Confers Protection from Natural Killer Cell–mediated Lysis , 1998, The Journal of experimental medicine.

[117]  J. Bell,et al.  HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C , 1998, Nature.

[118]  S. Shiobara,et al.  [Therapeutic effect of donor leukocyte transfusion in relapsing marrow transplants in Japan]. , 1997, [Rinsho ketsueki] The Japanese journal of clinical hematology.

[119]  W. Wilmanns,et al.  Adoptive immunotherapy in canine chimeras. , 1997, Transplantation.

[120]  C. Ware,et al.  Fas involvement in human NK cell apoptosis: lack of a requirement for CD16‐mediated events , 1997, Journal of leukocyte biology.

[121]  Robert H. Collins,et al.  Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[122]  H. Kantarjian,et al.  CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. , 1995, Blood.

[123]  A Ferrant,et al.  Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. , 1995, Blood.

[124]  S. Mackinnon,et al.  Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. , 1995, Blood.

[125]  R. Giavazzi,et al.  Transfer of the HSV-tk gene into donor peripheral blood lymphocytes for in vivo modulation of donor anti-tumor immunity after allogeneic bone marrow transplantation. , 1995, Human gene therapy.

[126]  Eric O Long,et al.  Molecular clones of the p58 NK cell receptor reveal immunoglobulin-related molecules with diversity in both the extra- and intracellular domains. , 1995, Immunity.

[127]  M. Colonna,et al.  Cloning of immunoglobulin-superfamily members associated with HLA-C and HLA-B recognition by human natural killer cells. , 1995, Science.

[128]  S. Steinberg,et al.  T‐cell‐depleted allogeneic bone marrow transplantation for acute leukaemia using Campath‐1 antibodies and post‐transplant administration of donor's peripheral blood lymphocytes for prevention of relapse , 1995, British journal of haematology.

[129]  R. Champlin,et al.  Leukemia relapse after allogeneic bone marrow transplantation: a review. , 1994, Blood.

[130]  J. Goldman,et al.  Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse. , 1994, Blood.

[131]  D. Porter,et al.  Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. , 1994, The New England journal of medicine.

[132]  S. Thibodeau,et al.  Molecular remission occurring after donor leukocyte infusions for the treatment of relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. , 1992, Bone marrow transplantation.

[133]  A. Rimm,et al.  T-cell depletion of HLA-identical transplants in leukemia. , 1991, Blood.

[134]  T. Whiteside,et al.  Increased proliferation, lytic activity, and purity of human natural killer cells cocultured with mitogen-activated feeder cells. , 1991, Cellular immunology.

[135]  R. Truitt,et al.  Impact of pretransplant conditioning and donor T cells on chimerism, graft-versus-host disease, graft-versus-leukemia reactivity, and tolerance after bone marrow transplantation. , 1991, Blood.

[136]  C. Marosi,et al.  Prognostic significance of surface marker expression on blasts of patients with de novo acute myeloblastic leukemia. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[137]  A. Rimm,et al.  Graft-versus-leukemia reactions after bone marrow transplantation. , 1990, Blood.

[138]  K. Sullivan,et al.  Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. , 1989, The New England journal of medicine.

[139]  H. Ljunggren,et al.  Selective rejection of H–2-deficient lymphoma variants suggests alternative immune defence strategy , 1986, Nature.

[140]  R. Brookmeyer,et al.  Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. , 1983, The New England journal of medicine.

[141]  E. Reinherz,et al.  Generation of a cloned NK cell line derived from the "null cell" fraction of human peripheral blood. , 1982, Journal of immunology.

[142]  R. Kiessling,et al.  An Analysis of the Murine NK Cell as to Structure, Function and Biological Relevance , 1979, Immunological reviews.

[143]  G. Trinchieri,et al.  Human natural killer cells. , 1979, Transplantation proceedings.

[144]  I. Brodsky,et al.  Bone marrow transplantation in acute leukemia. , 1977, Pennsylvania medicine.

[145]  P. Neiman,et al.  One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. , 1977, Blood.

[146]  E. Goulmy,et al.  ALLOIMMUNITY TO HUMAN H-Y , 1976, The Lancet.

[147]  R. Storb,et al.  Infusion of donor lymphocytes into stable canine radiation chimeras: implications for mechanism of transplantation tolerance. , 1976, Journal of immunology.

[148]  R Storb,et al.  Bone-marrow transplantation (first of two parts). , 1975, The New England journal of medicine.

[149]  R. Steinman,et al.  Identification of a novel cell type in peripheral lymphoid organs of mice. IV. Identification and distribution in mouse spleen , 1975, The Journal of experimental medicine.

[150]  R. Slavin,et al.  The use of cyclophosphamide for clinical marrow transplantation. , 1972, Transplantation proceedings.

[151]  D. Turk.  The bacteriology of chronic bronchitis. , 1971, Journal of clinical pathology.

[152]  R. Storb,et al.  TRANSPLANTATION OF STORED ALLOGENEIC BONE MARROW IN DOGS SELECTED BY HISTOCOMPATIBILITY TYPING , 1969, Transplantation.

[153]  E. Simmons,et al.  STUDIES ON IMMUNOLOGICAL UNRESPONSIVENESS DURING SECONDARY DISEASE III. Effect of Donor Strain on Acquisition of Mutual Tolerance , 1969, Transplantation.

[154]  R. Storb,et al.  CYTOTOXIC TYPING ANTISERA FOR MARROW GRAFTING IN LITTERMATE DOGS , 1968, Transplantation.

[155]  G. Mathé,et al.  Investigation on a test of histocompatibility for allogeneic grafts. 3. A study in man. , 1966, Transplantation.

[156]  M. Tubiana,et al.  SUCCESSFUL ALLOGENIC BONE MARROW TRANSPLANTATION IN MAN: CHIMERISM, INDUCED SPECIFIC TOLERANCE AND POSSIBLE ANTI-LEUKEMIC EFFECTS. , 1965, Blood.

[157]  G. Mathé,et al.  INVESTIGATION ON A TEST OF HISTOCOMPATIBILITY FOR ALLOGENEIC GRAFTS: II. A Study on Rabbits* , 1963, Transplantation.

[158]  O. Vos,et al.  “KILLING EFFECT” OF INJECTED LYMPH NODE CELLS IN HOMOLOGOUS RADIATION CHIMERAS , 1962, Plastic and reconstructive surgery.

[159]  J. Loutit,et al.  Treatment of Murine Leukaemia with X‐Rays and Homologous Bone Marrow: II , 1957, British journal of haematology.

[160]  J. Loutit,et al.  Treatment of Murine Leukaemia with X Rays and Homologous Bone Marrow , 1956, British medical journal.

[161]  A. Borkhardt,et al.  Significance of Frequencies, Compositions, and/or Antileukemic Activity of (DC-stimulated) Invariant NKT, NK and CIK Cells on the Outcome of Patients With AML, ALL and CLL , 2017, Journal of immunotherapy.

[162]  E. Yvon,et al.  Cord blood: a promising source of allogeneic natural killer cells for immunotherapy. , 2015, Cytotherapy.

[163]  T. Lamparelli,et al.  DLI after haploidentical BMT with post-transplant CY , 2015, Bone Marrow Transplantation.

[164]  A. Madrigal,et al.  Differential activation of cord blood and peripheral blood natural killer cells by cytokines. , 2015, Cytotherapy.

[165]  W. Leung,et al.  Enhanced cytotoxic function of natural killer and CD3+CD56+ cells in cord blood after culture. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[166]  A. Spyridonidis,et al.  High alloreactivity of low-dose prophylactic donor lymphocyte infusion in patients with acute leukemia undergoing allogeneic hematopoietic cell transplantation with an alemtuzumab-containing conditioning regimen. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[167]  C. Schiffer,et al.  Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia , 2012, Leukemia.

[168]  M. Robin,et al.  Evidence for anti-tumour effect of allogeneic haematopoietic SCT in cases without sustained donor engraftment , 2010, Bone Marrow Transplantation.

[169]  M. Perro,et al.  WT1-specific T cell receptor gene therapy: improving TCR function in transduced T cells. , 2008, Blood cells, molecules & diseases.

[170]  A. Barrett,et al.  Allogeneic stem cell transplantation for myelodysplastic syndrome. , 2008, Seminars in hematology.

[171]  D. Jain,et al.  Memory T cells in GVHD and GVL. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[172]  N. Chao.  Memory T cells. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[173]  J. Apperley.  Managing the patient with chronic myeloid leukemia through and after allogeneic stem cell transplantation. , 2006, Hematology. American Society of Hematology. Education Program.

[174]  Review Articles (434 articles) , 2005 .

[175]  F. Appelbaum,et al.  Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants. , 2004, Blood.

[176]  M. Bonamino,et al.  Prophylactic donor lymphocyte infusions after moderately ablative chemotherapy and stem cell transplantation for hematological malignancies: high remission rate among poor prognosis patients at the expense of graft-versus-host disease , 2001, Bone Marrow Transplantation.

[177]  C. Craddock,et al.  Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. , 2000, Blood.

[178]  H. Rammensee,et al.  Self tolerance of natural MHC class I ligands. , 1993, International reviews of immunology.

[179]  M. Horowitz,et al.  Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. , 1993, Blood.

[180]  R. Hoffman,et al.  Human CD34+ HLA-DR- bone marrow cells contain progenitor cells capable of self-renewal, multilineage differentiation, and long-term in vitro hematopoiesis. , 1991, Blood cells.

[181]  H. Ljunggren,et al.  In search of the 'missing self': MHC molecules and NK cell recognition. , 1990, Immunology today.

[182]  W. Wilmanns,et al.  Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. , 1990, Blood.

[183]  G. Trinchieri,et al.  Preferential proliferation of natural killer cells among peripheral blood mononuclear cells cocultured with B lymphoblastoid cell lines. , 1987, Natural immunity and cell growth regulation.

[184]  A. Steele,et al.  Recovery of hematologic competence without engraftment following attempted bone marrow transplantation for aplastic anemia: Report of a case with diffusion chamber studies. , 1977, Experimental hematology.

[185]  Sensenbrenner Ll,et al.  Recovery of hematologic competence without engraftment following attempted bone marrow transplantation for aplastic anemia: Report of a case with diffusion chamber studies. , 1977 .

[186]  J. Gibbs,et al.  Reduced sensitivity of F-1 hybrid rats to re-challenge with parental strain spleen cells. , 1966, Clinical and experimental immunology.